10X Fund LP
10
570K
1
1
0.90
1
- Stages of investment
- Areas of investment
Summary
The venture was found in North America in United States. The main office of represented VC is situated in the Niceville.
The typical case for the fund is to invest in rounds with 1 participant. Despite the 10X Fund LP, startups are often financed by National Institutes of Health. In the next rounds fund is usually obtained by National Institutes of Health.
This organization was formed by James Czirr, Rod D. Martin.
The real fund results show that this VC is 10 percentage points less often commits exit comparing to other companies. The top amount of exits for fund were in 2012. The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2009. Comparing to the other companies, this 10X Fund LP performs on 19 percentage points less the average number of lead investments. The common things for fund are deals in the range of 100 thousands - 1 million dollars.
Among the various public portfolio startups of the fund, we may underline Galectin Therapeutics Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Investments analytics
Analytics
- Total investments
- 10
- Lead investments
- 1
- Exits
- 1
- Follow on index
- 0.90
- Investments by industry
- Biopharma (10)
- Pharmaceutical (10)
- Biotechnology (10)
- Investments by region
-
- United States (10)
- Peak activity year
- 2009
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 21
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Galectin Therapeutics | 02 Feb 2010 | Biotechnology, Pharmaceutical, Biopharma | Early Stage Venture | 325K | United States, Georgia |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.